Bayer looks to Xarelto to take it past the ¥200bn mark in Japan
This article was originally published in Scrip
Executive Summary
Bayer Yakuhin, Bayer's pharmaceutical subsidiary in Japan, is confident that its sales will surpass the ¥200 billion ($2.43 billion) level next year, driven by new launches and despite this month's industry-wide reimbursement price cut.